Foghorn Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Foghorn Therapeutics Inc. on June 26, 2024. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Cambridge, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders and both were approved:
- Election of Directors: Scott Biller, Ph.D., Thomas J. Lynch, M.D., and Michael Mendelsohn, M.D. were elected as Class I directors for three-year terms.
- Ratification of Auditors: Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voting Statistics:
- Total shares entitled to vote: 42,585,616
- Total shares present or represented: 30,381,145
- Director Election Results:
- Scott Biller, Ph.D.: 20,425,665 For; 4,930,514 Against; 10,337 Abstentions
- Thomas J. Lynch, M.D.: 24,052,377 For; 1,293,218 Against; 20,921 Abstentions
- Michael Mendelsohn, M.D.: 22,357,558 For; 2,988,038 Against; 20,920 Abstentions
- Broker non-votes on director election: 5,014,629
- Auditor Ratification Results: 30,355,319 For; 10,376 Against; 15,450 Abstentions. No broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the three-year directorships for the newly elected Class I directors.
- Review the detailed Proxy Statement filed on May 3, 2024, for full context on the proposals and management discussion.
- Note the significant number of broker non-votes (5,014,629) regarding the election of directors, indicating shares held by brokers that were not voted due to lack of instructions.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.